Angioblast's lead products target significant unmet medical needs. The initial clinical indications targeted by Angioblast affect several million patients annually in the United States alone:
Initial Indications Targeted |
Annual US Patient Population |
Heart attacks |
1,100,000 |
Heart failure |
550,000 |
Peripheral artery disease |
400,000 |
Skin ulcers |
800,000 |
